Antibiotics fight infections caused by bacteria. They should not be used to treat infections caused by viruses (such as the flu) or types of fungi, which include yeasts and molds.
Site Search
Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials
Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases
Bill Would Remove Financial Penalties for Participating in Research Studies
CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
CFF-Championed Bill Eliminates Barriers to Participation in Clinical Trials for People with CF and other Rare Diseases
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.